title: Consolidation with bortezomib and dexamethasone following risk-adapted melphalan and stem cell transplant in systemic AL amyloidosis.
authors.affiliation: Memorial Sloan-Kettering Cancer Center, NY, USA.
authors.forename: H
authors.initials: H
authors.lastname: Landau
authors.forename: H
authors.initials: H
authors.lastname: Hassoun
authors.forename: C
authors.initials: C
authors.lastname: Bello
authors.forename: E
authors.initials: E
authors.lastname: Hoover
authors.forename: E R
authors.initials: ER
authors.lastname: Riedel
authors.forename: S D
authors.initials: SD
authors.lastname: Nimer
authors.forename: R L
authors.initials: RL
authors.lastname: Comenzo
mesh_terms: D001897:Boronic Acids / Q000008:administration & dosage / Q000627:therapeutic use*; D000069286:Bortezomib; D003131:Combined Modality Therapy; D003907:Dexamethasone / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D008558:Melphalan / Q000008:administration & dosage / Q000627:therapeutic use*; D011719:Pyrazines / Q000008:administration & dosage / Q000627:therapeutic use*; D033581:Stem Cell Transplantation
chemical_list: D001897:Boronic Acids; D011719:Pyrazines; D000069286:Bortezomib; D003907:Dexamethasone; D008558:Melphalan